{
    "clinical_study": {
        "@rank": "92520", 
        "arm_group": [
            {
                "arm_group_label": "brachytherapy", 
                "arm_group_type": "Experimental", 
                "description": "Iodine-125 radioactive seeds permanent interstitial implantation brachytherapy"
            }, 
            {
                "arm_group_label": "IMRT", 
                "arm_group_type": "Active Comparator", 
                "description": "IMRT (intensity-modulated radiation therapy), 6 Millivolt (MV)-x fractionated irradiation, 1 time/day, 5 times a week, till the end. Add up to 33 times."
            }
        ], 
        "brief_summary": {
            "textblock": "-  To compare the efficacy of Iodine-125 radioactive seeds implantation versus IMRT to\n           treat inoperable salivary gland carcinoma.\n\n        -  To compare the safety of Iodine-125 radioactive seeds implantation versus IMRT to treat\n           inoperable salivary gland carcinoma."
        }, 
        "brief_title": "Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer", 
        "completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Salivary Gland Cancer", 
        "condition_browse": {
            "mesh_term": "Salivary Gland Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The target population are those patients with inoperable salivary gland derived primary or\n      recurrent cancer, including local advanced primary salivary gland cancer which could not be\n      resected completely; recurrent salivary gland cancer which could not be resected completely;\n      T3/T4 tumor which could not tolerate surgery due to severe combined disease. The subjects\n      would be divided into Iodine-125 radioactive seeds permanent interstitial implantation\n      brachytherapy and intensity-modulated radiation therapy randomly. During the follow-up\n      period, the efficacy and the safety index would be monitored."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients are diagnosed  histologically as primary or recurrent salivary gland cancers\n             that may occur in either major salivary glands or minor salivary glands.\n\n          -  The inoperable circumstance include:  Primary or recurrent salivary gland cancers\n             that could not be resected completely or could not get negative incision.\n\n          -  T3/T4 tumor patients with severe medical comorbidities could not accept the high risk\n             of perioperative complications.\n\n          -  At least one measurable tumor or focus (according to RESIST 1.1 Standard).\n\n          -  Karnofsky score> 60.\n\n          -  Survival time predicted  \u2265 3months;\n\n          -  HGB\u22659 g/dL, WBC\u22653.0\u00d710^9/L, NEUT\u22651.5\u00d710^9/L, platelet count (PLT)\u2265 100\u00d710^9/L;\n             TBIL\u22641.5 upper limit of normal, Alanine aminotransferase (ALT)/AST\u22643 upper limit of\n             normal; Cera\u22641.5 upper limit of normal.\n\n          -  Male or female with  fertility  in the experiment   are  willing   to   take\n             contraceptive measures.\n\n        Exclusion Criteria:\n\n          -  Radioactive therapy history of head and neck.\n\n          -  Suffering from other malignant tumor in recent five years, except skin basal cell\n             carcinoma or carcinoma in situs of cervix.\n\n          -  Chemotherapy history.\n\n          -  Receiving other effective therapy.\n\n          -  Distant metastases.\n\n          -  Pathologic result as squamous cell carcinoma.\n\n          -  Neurological or mental abnormalities which affect cognitive ability.\n\n          -  Severe cardiovascular and cerebrovascular diseases, such as heart failure (NYHA\n             III-IV class), uncontrolled coronary heart disease, cardiomyopathy, uncontrolled\n             arrhythmias, uncontrolled hypertension, myocardial infarction or cerebral infarction\n             within past six months.\n\n          -  Active serious clinical infections :> Class 2 NCI-Common Toxicity Criteria for\n             Adverse Effects (CTCAE) Version 4.0 within 14 days before randomization, including\n             active tuberculosis.\n\n          -  HIV infection or active hepatitis B or hepatitis C.\n\n          -  Uncontrolled systemic diseases, such as poorly controlled diabetes mellitus.\n\n          -  Medical history of interstitial lung disease, such as interstitial pneumonia,\n             pulmonary fibrosis, or baseline chest X-ray / CT showed evidence of interstitial lung\n             disease;\n\n          -  Pregnancy (via urine \u03b2-human chorionic gonadotropin test to determine) or\n             breastfeeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02048254", 
            "org_study_id": "PUCRP201308"
        }, 
        "intervention": [
            {
                "arm_group_label": "brachytherapy", 
                "intervention_name": "brachytherapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "IMRT", 
                "intervention_name": "IMRT", 
                "intervention_type": "Radiation", 
                "other_name": "intensity-modulated radiation therapy"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "inoperable salivary gland cancer", 
            "brachytherapy", 
            "intensity-modulated radiation therapy"
        ], 
        "lastchanged_date": "January 27, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Randomized Control Trial (RCT) of Using Iodine-125 Brachytherapy Versus Intensity-modulated Radiation Therapy (IMRT) to Treat Inoperable Salivary Gland Cancer", 
        "other_outcome": [
            {
                "description": "Measured using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Scale Quality of life Questionnaire (QLQ)-C30 (V3.0) and the QLQ-H & N35 (V1.0) of quality of life questionnaire.", 
                "measure": "quality of life", 
                "safety_issue": "Yes", 
                "time_frame": "2 year"
            }, 
            {
                "description": "according to NCI-Common Toxicity Criteria Adverse Event \uff08CTCAE\uff094.0 standard", 
                "measure": "The incidence of radiation-related adverse reactions", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "overall_contact": {
            "email": "kqlsm@126.com", 
            "last_name": "Shuming Liu, Doctor", 
            "phone": "0086-13520162017"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "According to  Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 standard, tumor progressing during the treatment and follow up period means local control failure, which include the sum of diameters of  local and region target focus increases \u226520% or \u22655mm; new focus emerges at local or region area; metastases or secondary primary tumor would not be concluded.", 
            "measure": "local control rate", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02048254"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University", 
            "investigator_full_name": "Jianguo Zhang", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "progression-free survival is definite as the time of death of tumor progression event emerges from the patient was randomize. According to  Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 standard, tumor progressing during the treatment and follow up period means local control failure, which include the sum of diameters of local and region target focus increases \u226520% or \u22655mm; new focus emerges at local or region area; metastases or secondary primary tumor would not be concluded. No respondent means the tumor advances at the first day.", 
                "measure": "progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Refers to the result from a random start time to death of any cause. Records from the beginning of the random time to time of any cause of death. Shedding of subjects censored cases recorded censored time.", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization until the date of death from any cause, assessed up to 2 years"
            }
        ], 
        "source": "Peking University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}